Peptides as NS3-serine protease inhibitors of hepatitis C virus

US7169760B2 · kind B2 · utility

Assignees

• SCHERING CORPORATION · US
• Dendreon Corporation · US

Inventors

• Anil K. Saksena · Upper Montclair, US
• Viyyoor M. Girijavallabhan · Parsippany, US
• Stephane L. Bogen · Somerville, US
• Raymond G. Lovey · West Caldwell, US
• Edwin Jao · Hackettstown, US
• Frank Bennett · Piscataway, US
• Jinping L. Mc Cormick · Edison, US
• Haiyan Wang · Cranbury, US
• Russell E. Pike · Stanhope, US
• Yi Liu · San Diego, US
• Tin-Yau Chan · Edison, US
• Zhaoning Zhu · Plainsboro, US
• Ashok Arasappan · Bound Brook, US
• Kevin X. Chen · Edison, US
• Srinkanth Venkatraman · Fords, US
• Tejal Parekh · Mountain View, US
• Patrick A. Pinto · Mine Hill, US
• Bama Santhanam · Bound Brook, US
• F. George Njoroge · Hackettstown, US
• Ashit K. Ganguly · Upper Montclair, US
• Henry A. Vaccaro · South Plainfield, US
• Scott Jeffrey Kemp · San Diego, US
• Odile Esther Levy · San Diego, US
• Marguerita Lim-Wilby · Village of La Jolla, US
• Susan Y. Tamura · San Diego, US

Key dates

• Filing date: Jul 19, 2001
• Grant date: Jan 30, 2007
• Expiry date: Nov 6, 2022

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07K7/02
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention discloses novel peptide compounds which have HCV protease inhibitory activity as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising such compounds as well as methods of using them to treat disorders associated with the HCV protease.